Table 5:
Characteristics of severe psoriasis patients at baseline and at one-year following therapy for psoriasis.
| Parameter | Baseline (N=30) |
Follow-up (N=30) |
p- value |
|---|---|---|---|
| Demographics and medical history | |||
| Age, years | 51.1 ± 12.0 | 52.3 ± 12.3 | - |
| Males | 23 (77%) | 23 (77%) | - |
| Hypertension | 11 (37%) | 9 (30%) | 0.56 |
| Hyperlipidemia | 15 (50%) | 16 (53%) | 0.65 |
| Type 2 diabetes mellitus | 4 (13%) | 3 (10%) | 0.32 |
| Current tobacco use | 3 (10%) | 3 (10%) | 1.00 |
| Lipid treatment | 10 (33%) | 10 (33%) | 1.00 |
| Body mass index | 30.3 ± 7.2 | 29.4 ± 6.7 | 0.26 |
| Waist-to-hip ratio | 0.99 (0.95 - 1.05) | 0.98 (0.92 - 1.01) | 0.54 |
| Clinical and laboratory values | |||
| Systolic blood pressure, mmHg | 122.9 ± 15.6 | 120.2 ± 16.3 | 0.12 |
| Diastolic blood pressure, mmHg | 73.8 ± 10.5 | 70.5 ± 11.4 | 0.07 |
| Total cholesterol, mg/dL | 172.8 ± 36.0 | 172.5 ± 39.0 | 0.99 |
| HDL cholesterol, mg/dL | 51.9 ± 15.2 | 55.0 ± 17.0 | 0.25 |
| LDL cholesterol, mg/dL | 100.5 ± 32.4 | 95.4 ± 36.0 | 0.44 |
| Triglycerides, mg/dL | 119.8 ± 75.3 | 112.0 ± 52.7 | 0.67 |
| Framingham risk score | 3.5 (1.0 – 6.0) | 4.0 (1.0 – 7.0) | 0.04 |
| C-reactive protein, mg/L | 3.0 (1.6 – 8.7) | 1.5 (0.8 – 4.1) | 0.01 |
| HOMA-IR* | 3.5 (1.6 – 5.3) | 3.9 (2.1 – 7.3) | 0.16 |
| Cholesterol efflux capacity | 0.89 ± 0.14 | 0.96 ± 0.13 | 0.01 |
| Psoriasis characterization | |||
| Psoriasis area severity index score | 15.5 (12.5 – 23.2) | 5.9 (3.4 – 10.4) | <0.001 |
| Total body surface area index | 28.1 (20.2 – 43.5) | 6.6 (1.9 – 14.0) | <0.001 |
| Psoriasis treatment breakdown | |||
| Topical | 20 (67%) | 19 (63%) | - |
| Phototherapy | 7 (23%) | 9 (30%) | - |
| Systemic | 4 (13%) | 5 (17%) | - |
| Biologic | 9 (30%) | 18 (60%) | - |
| Types of biologic treatment | |||
| Anti-TNF therapy | 3 | 11 | - |
| Anti IL12/23 therapy | 3 | 3 | - |
| Anti IL17 therapy | 3 | 4 | - |
| Amygdalar activity (18FDG PET/CT) | |||
| Amygdalar FDG uptake | 1.12 ± 0.11 | 1.05 ± 0.09 | 0.006 |
| Aortic vascular inflammation (18FDG PET/CT) | |||
| Target-to-background ratio | 1.78 ± 0.32 | 1.67 ± 0.26 | 0.01 |
| Coronary plaque burden (x100) | |||
| Total burden, mm2 | 1.37 ± 0.73 | 1.31 ± 0.63 | 0.21 |
| Non-calcified burden, mm2 | 1.29 ± 0.69 | 1.24 ± 0.60 | 0.23 |
| Hematopoietic system activity (18FDG PET/CT) | |||
| Bone marrow (SUV† max) | 4.05 ± 1.15 | 3.70 ± 1.06 | <0.001 |
| Spleen (SUV† max) | 3.55 ± 1.03 | 3.74 ± 1.19 | 0.10 |
Values reported in the table as Mean ± SD or Median (IQR) for continuous data and N (%) for categorical data. P value ≤ 0.05 deemed significant. P values were calculated by using student’s t-test or Mann-Whitney U test for continuous variables and Pearson’s chi-squared test for categorical variables.
*
HOMA-IR: Homeostasis model assessment of insulin resistance,
†
SUV: Standardized uptake value.